Iconovo

Executive Summary

Iconovo is a Swedish inhalation drug delivery company specializing in proprietary dry powder inhaler (DPI) devices and tailored powder formulations. Founded in 2010 and based in Malmö, the company partners with pharmaceutical firms to develop inhaled medicines for respiratory care and is expanding into systemic delivery for other therapeutic areas. Iconovo leverages its proprietary technology platform to offer end-to-end development services, from formulation to device design, aiming to improve patient outcomes through innovative inhalation solutions. With a focus on strategic collaborations, the company seeks to accelerate the development of novel inhaled therapies and capture value in the growing respiratory drug delivery market. As a private entity, Iconovo's progress is tied to its ability to secure partnerships and advance its pipeline, positioning it as a potential acquisition target or IPO candidate in the future.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a new partnership for systemic delivery programme70% success
• Q4 2026Initiation of a clinical trial for an inhaled respiratory product50% success
• Q2 2026Grant of a key patent covering proprietary DPI technology80% success